Teva Presents New Long-term Safety Data from SOLARIS Trial Supporting Olanzapine LAI as a Potential Treatment Option for Schizophrenia.

Teva Pharmaceuticals announced the presentation of 10 posters at the 2025 Psych Congress Annual Meeting, showcasing long-term safety data from the SOLARIS trial. The results indicate no incidence of post-injection delirium/sedation syndrome (PDSS) in participants taking olanzapine LAI (TEV-'749). Additionally, new data evaluating UZEDY, an extended-release injectable suspension of risperidone, found that it was associated with a shorter length of hospitalization compared to Invega Sustenna. Teva aims to develop innovative medicines to address unmet needs in complex mental health conditions.